Entities

DTCP, Digital Transformation Capital Partners, is a global investment-management platform specializing in enterprise software, digital infrastructure and mission-critical technologies. Its Growth strategy backs companies building AI, cloud infrastructure, cybersecurity and business software, using financial benchmarking and operating support to help them scale. Its Infra strategy invests in the networks and facilities that support digital services, including fiber, mobile infrastructure and data centers. DTCP Defence backs European and strategically relevant allied technology businesses in artificial intelligence, autonomous systems, cyber defence, secure communications and space, with a focus on early-growth and growth-stage equity investments. The platform was founded in 2015 and is headquartered in Hamburg with an international investment and operating team. Its published legal entity is Digital Transformation Capital Partners GmbH, licensed in Germany as an investment firm providing investment-advisory services. Identity and source audit (October2026): DTCP Growth is this existing platform’s enterprise-software growth strategy, not a newly created unrelated manager. The current legal notice identifies Digital Transformation Capital Partners GmbH, Hamburg HRB162778, VATDE339826566 and LEI391200N4AVRS726J8498; managing directors Vicente Vento Bosch and Martin Klima and authorised signatory Philipp von Bismarck. Its published WpIG permissions concern investment brokerage/advice without holding client assets or dealing for its own account in those services. The Luxembourg fund-advisory entity Digital Transformation Capital Partners Luxembourg Sarl, external AIFMs, legal funds, Deutsche Telekom corporate sponsor and strategy brands are distinct capacities; this umbrella investor affiliation does not assert every company check was subscribed from German-adviser treasury or an unproved specific legal fund. The current website names64staff across Growth, Infra, Defence and the shared platform, plus18external senior advisers. All82canonicalpeople and role IDs are reused and preserved. Sixty-three previously missing currentstaff portraits are added from authentic individually named own photographs, visually inspected; Jack Young’s existing authentic image, biography and outside roles remain intact. Staff biographies now contain source-based professional summaries. The senior-adviser page publishes professional capacities without portrait assets or detailedcareer biographies, leaving18portrait gaps explicitly documented. Senior advisers are external, not ordinarystaff or automaticallypersonal investors. Own directory headings and biographies disagree about Jonas Janssen (ManagingDirector versusPrincipal) and Claudius Laskawy (Principal versusVicePresident); existing heading-based titles are retained and discrepanciesqualified, not silently overwritten. The platform’s flagship fund history is source-qualified. DeutscheTelekom’s2021primarycapital-markets presentation identifies actualcommittedfund sizes GrowthIUSD140M, GrowthIIUSD350M and InfraIEUR200M, distinguished from investment deployment, portfolio fairvalue, corporate transactionproceeds and targetcapital. Exact historicalclosingdays are notproved and remainNULL. GrowthIII’s June26,2024finalclose and a separateearly-stageinitialclose totalUSD450M collectively; existingGrowthIIIstandaloneamountNULL is preserved. DIVII’s April18,2024finalclose plus associatedco-investmentvehicles totalaboutEUR1.6B collectively; standaloneDIVIIamountNULL avoids allocatingtheaggregatetoonefund. DIVIIMatrixCoInvestIISCSp and InchargeFundISCSpSICAVRAIF are source-provedseparatelegalvehicles withunknownclosedamount/day, notduplicatedcashamounts. ExistingLibertyDefenceFundIactualEUR455M firstcloseSeptember24,2026 is preserved, not upgradedtofinalcloseor earlierEUR500Mtarget. NoAUM, investorbudget, return, commitmenttoportfolioorplannedfundraising is treatedasadditionalpaidcompanycash. OwnGrowthportfolio confirms enterpriseAI/cloud/cybersecurity/robotics investments and is queued for issuer-by-issuerprimaryfunding/clinicalaudits; affiliation alone does not establish a cashround, legalfundallocation or exactbuyer ticket. SPREAD’s own April29,2026USD30MSeriesB explicitlynamesnewbuyerDTCPGrowth; issuerbatch786 ownsONEqualifiedparticipation underretainedInvestor4096 andround27657, ticketNULL. No duplicateDTCPGrowthorganization or personalmanagementcheck is inferred.

Historical name of Energize Capital, the Chicago energy, climate and industrial technology investment firm. Energize announced its rebrand from Energize Ventures to Energize Capital on July 27, 2023. The enriched current profile is GoldiEnergizeCapital / Investor3966. This legacy identity remains to preserve its existing protected source references and participation record; it does not represent a separate currently verified firm.

Glasswing Ventures is a Boston venture capital firm that provides the first institutional capital to pre-seed and seed startups building AI-native and frontier technologies for enterprise software and cybersecurity. Its investment team, AI engineers and operating partners support founders with product development, commercialization, hiring and go-to-market strategy, backed by a network of technical and industry advisors.

Guidewire Software, Inc. is a Delaware corporation incorporated September20,2001, headquartered in San Mateo, California and listed on the NYSE as GWRE. It provides a cloud technology platform for property-and-casualty insurers combining core policy, billing and claims systems with digital workflows, analytics, and predictive/generative AI. InsuranceSuite, InsuranceNow and the Guidewire Cloud Platform support underwriting, policy administration and insurance operations. This retained historical database InvestmentFirm classification represents the actual corporate strategic investor; the legal issuer is a software company rather than an independent LP-backed venture fund. Guidewire Ventures is its internal strategic venture-capital arm, investing in early-stage software, data and analytics businesses supporting the insurance ecosystem. Its own investment FAQ explicitly states that investments are made from the corporate balance sheet and that it has no dedicated investment fund. The three published venture-team members are scoped separately from corporate executives and directors. Customer partnerships, Insurtech Vanguards programme membership, director affiliations and acquisitions are not automatically investment checks. The issuer names Guidewire as a strategic participant in Sixfold’s actual USD30M SeriesB announcedJanuary29,2026; the exact subscribing subsidiary and individual ticket are unpublished. The corporate directories publish eleven executive leaders and nine directors, with one person overlapping, plus three distinct investment-arm team members. Current titles are source-qualified: the leadership page and IR directory differ for David Laker/Michael Mahoney, and reported2026 commercial-leadership succession has not been independently reconciled from a currently accessible issuer transcript. Published roster size is not total headcount. Corporate2018USD400M and2024USD690M convertible-note issuance disclosed in the2026 annual report are corporate debt, not venture-fund closes; the USD300M revolving facility is reported undrawn atJuly31,2026 and is not raised cash.

German venture-capital platform backing technology companies from pre-seed and seed through growth. It invests across digital technology and AI, industrial and climate-related deep tech, life sciences and chemistry, supporting startups with capital, investment expertise and an industry network.

Investissement Québec is Quebec's public economic-development and financing organization. It provides loans, equity investment and business support, including innovation and technology services, and administers government programs such as Impulsion PME for emerging companies.

Latitude is Phoenix Court’s breakout and early-growth investment strategy, backing technology companies from Series B onward through primary and secondary investments. It is the growth-stage sister fund to LocalGlobe, which specialises in pre-seed and seed; latitude.vc redirects to the current Phoenix Court Latitude fund page. Its published strategy emphasises founder relationships and participation alongside lead investors, particularly in the UK, Europe and Israel, across AI, deep technology, healthcare, robotics and other technology markets. Automata’s own February22,2022 USD50M Series B announcement names returning investor Latitude Ventures, and the current manager’s Automata portfolio page explicitly assigns the company to LocalGlobe and Latitude. The UK website legal operator is Phoenix Court Group Limited, Companies House12156857 and FCA915004. A separate March2026 SEC exempt-reporting-adviser filing identifies Guernsey Phoenix Court Fund Management Limited, CRD325921, and exact Latitude LP funds and their general partners. These legal units and fund vehicles are not treated as interchangeable cash subscribers. The current directory is a shared Phoenix Court investment, operations, value-creation and board platform; linked roles explicitly identify that shared capacity, rather than duplicate independent employment at every sibling fund. The official profile picture is the authentic shared Phoenix Court mark used on Latitude’s current fund page; a separate current Latitude-only graphic is not published there. The retained Latitude investor4081 is distinct from LocalGlobe1615, PhoenixCourtGroup2841, unrelated Latitude investment firms and the French launch-vehicle company.

Luminar Ventures is a Stockholm-based venture capital manager backing Nordic technology companies at pre-seed and seed. It invests across software, AI, fintech, digital health, consumer technology and the energy transition, working with founders on building products, recruiting and developing businesses with international markets. The firm publishes an initial investment range of EUR500,000 to EUR2.5 million and supports its companies through investment staff, operating partners and an angel network. Its portfolio includes industrial AI, machine intelligence, simulation software and clean-energy infrastructure.

Top Tier Capital Partners, LLC (TTCP) is a San Francisco-based venture capital investment specialist managing primary fund commitments, venture secondaries and direct co-investments, with offices in San Francisco, Boston and London. Its predecessor fund-of-funds business began within Paul Capital in1999, and the current independent manager spun out in2011. The current public directory lists38 team members, led by General Partner and CEO Garth Timoll, Sr., General Partner and CIO Sean Engel, and Chairman David York. Its exposure to AI and deep technology spans both investments in venture managers and direct technology companies; fund-manager affiliations are distinct from startup investments. Its named funds include Top Tier Venture Capital IX, Venture Velocity Funds3and4 and a dedicated European venture fund. The USD925M2022 headline combined a USD503.5M VelocityFund4 close with related separate accounts; aggregate AUM and multicounterpart capital headlines are not single-fund sizes. TTCP is distinct from Teamworthy Ventures and from Minnesota healthcare investor TTCapitalPartners.

UVC Partners is a European B2B technology venture capital firm founded in 2011, with offices in Munich and Berlin. It backs early-stage and growth-stage companies in deep tech, climate technology, mobility and software/AI, including quantum computing, fusion energy, aerospace, robotics and healthcare software. Its investment teams combine technical and operating experience with portfolio support in sales, industry partnerships, talent and financing. UVC is an independent partner of the UnternehmerTUM entrepreneurship ecosystem, giving founders access to its corporate and research network. The legal manager is Unternehmertum Venture Capital Partners GmbH. The firm’s separately constituted early-stage and growth funds have different investment mandates; manager-wide assets under management are not the size of either vehicle.

Software operating company providing creative, document and digital-experience products. Corporate investments are distinct from a standalone venture capital firm or separately named venture affiliate.

Costanoa Ventures is a venture capital firm investing from seed and Series A in technical founders building AI-enabled enterprise software, AI and data infrastructure, cybersecurity, financial technology and defense technology. Its BuilderOps operating team helps portfolio companies with recruiting, sales, marketing, product and company operations; its opportunity funds make later-stage follow-on investments in existing portfolio companies.

Energize Capital is a Chicago investment firm backing asset-light technologies for the energy transition, industrial digitization, decarbonization and critical infrastructure. Its Ventures strategy backs Series A, B and C software and digital businesses, including AI forecasting, energy-storage optimization, computer vision and cybersecurity. Its Endurance strategy invests in mature, profitable software and services companies through control and minority transactions. Energize EDGE provides portfolio services in commercialization, finance and operations, impact, communications and people. The current firm history identifies establishment in 2017 with Invenergy; older announcements describe a 2016 strategy launch, so those dates are distinct. Formerly Energize Ventures, it adopted the Energize Capital name in July 2023. Verified closed Ventures funds are USD165M in 2018, USD330M in September 2021, and USD430M in June 2025 across Fund III and related vehicles. The July 2023 announcement reports USD300M across both growth funds, not a USD300M individual Fund II. Current platform scale and historic AUM are not additional fund closes.

M13 is a venture capital firm that invests early in technology companies building new markets. Its investors and operating team support founders with product development, revenue and go-to-market strategy, hiring, brand, data and company operations. Its portfolio includes enterprise AI, consumer technology and healthcare software.

Blue Cloud Ventures (BCV) is a New York growth-stage venture firm operated by Blue Cloud Management LLC, established inlate2012 by Mir Arif, Rami Rahal and Joel Lou. It invests in AI-enabled enterprise applications, data and AI infrastructure, developer tools, open-source software and cybersecurity businesses, with flexibility to lead, co-lead, participate and buy secondary shares. Its own April2023 release identifies the legal manager and Berlin office headed by venture partner Victor Yaw; operating partner Joel Lou is based inSingapore. The current public directory publishes14 investment and operating professionals plus21 advisory-network names, representing34 distinct people because Satish Tadikonda appears inboth groups. Advisory rows are qualified network affiliations; outside employer labels are reported directory background, not independently verified current executive appointments. Blue Cloud’s Amy Wang and Rami Rahal are distinct from CapacityBio’s PhD COO Amy Wang and MPMBioImpact’s PhD partner Rami Rahal, so separate qualified identities preserve those older profiles. The own founding story reports an initial12M fund; FINRA disclosures separately identify the first three legal LP vehicles and their general partners. FundIV reached a final close inDecember2021 with350M combined fund and co-investment commitments; the standalone LP amount is undisclosed, so350M is not assigned entirely to FundIV. FundV final close was announcedJune2,2026 with size undisclosed. Firm-wide AUM, cumulative portfolio counts and the broader entrepreneur-LP network are distinct from individual fund closings, cash called or company allocations. Existing institutional participations and protected financial records are retained, and the Templafy financing audit remains with its issuer owner.

Braidwell LP is a Stamford, Connecticut investment manager founded in2021 by Alex Karnal and Brian Kreiter. It finances companies improving human health across public and private markets using equity, debt and structured capital. Its published investment approach combines medical science, biostatistics, commercial research, financial structuring, portfolio engineering, data science and artificial intelligence. The firm describes Switchyard as its proprietary AI system for therapeutic investment research; claims about autonomous research or faster drug discovery are the manager’s statements rather than independently validated clinical outcomes. Its primary-funded companies span AI-enabled drug discovery, proteomics and diagnostics, neurological therapeutics and medical devices. Own publications identify Nick Myerberg as partner and head of AI and technology; the website publishes detailed founder biographies, while other named affiliations are separately qualified from official filings, issuer statements and first-person public profiles. Exact SEC identity is Delaware limited partnership Braidwell LP, CRD316988/SEC801-122966, distinct from general partner Braidwell Management LLC, fund GP Braidwell GP LLC and relying adviser Braidwell Labs PortfolioII Management LP. September22,2026 FormADV lists twelve legal private fund vehicles, including master-feeder and transaction structures and the new2026 LabsPortfolioII fund. Reported fund sales, AUM and listed equity holding values have different meanings and are not combined as new fundraising. February5,2026 FormD amendments report cumulative sales USD1,279,396,093 for the US feeder and USD2,865,734,000 for the offshore feeder; they are ongoing offering snapshots rather than final closed-fund announcements, and feeding into shared masters prevents double-counting. LabsPortfolioII’s September22,2026 FormD reports actualUSD102,445,000 sold against a USD250M target; the target and unsold147,555,000 are not cash raised. Cayman official notices record voluntary winding-up beginningDecember19,2025 for CompanionCMVLP and CompanionCMVMasterFundLP, despite their continued appearance in the latest ADV; their historical legal records are retained with that qualification. Institutional participation is linked once through this preserved manager brand when an issuer names Braidwell; an individual fund’s allocation or a partner’s personal investment is asserted only with explicit proof.

Dementia Discovery Fund (DDF) is an SV Health Investors venture strategy established in 2015 to create and finance biotechnology companies developing treatments for dementia and other neurodegenerative diseases. It invests in scientific approaches to Alzheimer's disease and related conditions, spanning target discovery, drug delivery, gene therapy, immune biology and disease mechanisms. Its first fund reached £250 million in 2018, and DDF II closed with $269 million in commitments in May 2025. Miles Gerson and Christian Jung co-lead the current team, supported by investment professionals, venture partners and a scientific advisory board. Its listed portfolio includes Alchemab, Amphista Therapeutics, AstronauTx, AviadoBio, Cerevance, Cumulus Neuroscience, Harness Therapeutics, LoQus23 Therapeutics, Montara Therapeutics, NRG Therapeutics and Violet Therapeutics.

Mubadala Investment Company is an Abu Dhabi sovereign investor owned by the government of Abu Dhabi. It invests across private equity, credit, real assets and UAE businesses, supporting economic diversification and long-term financial returns. Its UAE investments include venture financing for technology companies through the MENA Venture Capital Fund; Mubadala Capital is a separate asset-management subsidiary within the wider group.

Neo is the San Francisco technology venture-investment and founder community platform associated with legal adviser Neo Ventures, LLC. Its March31,2026 SEC Form ADV identifies CRD294621 and exempt-reporting-adviser file802-113137, with principal office595PacificAvenue; this is not an assertion of full SEC investment-adviser registration. Founded in2017, Neo combines venture funds with Scholars, accelerator and residency programmes to support technical founders. Its current published directory names nine operating-team professionals and separately identifies external residency mentors, scholar mentors and applicant interviewers; those community affiliations do not imply employment, company board seats or personal cash investments. The current residency directory publishes Emily Cohen as a Neo Partner alongside her Cognition operating role; the affiliation is qualified as published. Exact legal vehicles in the2026 ADV include fund vintages1.0,2.0,3.0,4.0, parallel A vehicles, opportunities funds and SPVs. Own April16,2025 announcement confirms USD320M raised for the fourth fund. Joint November2021 FormD/A reports USD150M fully sold for2.0/2.0a combined, includingGPcommitment; these platform totals are assigned once, not repeated across parallel vehicles. ADV gross asset values, portfolio valuations and AUM are not treated as original fund closes. AI and deep-tech portfolio examples published by Neo include Cursor, Pika, Cognition, Chai Discovery, Anterior, Kalshi and Bluesky. Comulate’s February11,2025 issuer release confirms earlier Neo backing, with earlier financing date, stage, amount and subscribing vehicle unpublished; this does not establish a participation in the new SeriesB. Existing Investor3889, private cash participation IDs and source attributions are preserved, and unrelated Neo namesakes are excluded.

New Leaf Venture Partners is a US healthcare technology investment firm formed in2005 when the healthcare team separated from the Sprout Group. It invests across startup, growth and public-company stages in biopharmaceuticals, information convergence and life-science tools, supporting clinically important and commercially viable healthcare innovation. Its relevance to AI and neuroscience is grounded in actual portfolio businesses: Neuronetics develops transcranial magnetic stimulation systems; CuraSen develops neurological treatments; Cleerly applies AI to cardiovascular imaging; BrightInsight supplies AI-enabled compliant digital health services; and Bluesight combines machine learning and medication-tracking technology. The published current team comprises co-founders and managing directors Ron Hunt and Vijay Lathi and operations/finance leader Craig Slutzkin. Historical funds include New Leaf Ventures I, II and III and New Leaf Growth Fund I; FundII closed at450million dollars in October2007. Other historical final closing amounts and dates remain unverified, and combined portfolio investment statistics include the partners’ prior Sprout career rather than exclusively NewLeaf checks. The manager is kept distinct from BioStar, unrelated NewLeaf-branded investors and the broader historical Sprout funds.

Early-stage venture firm partnering with globally ambitious founders across AI, infrastructure, fintech, cybersecurity, commerce and related technology markets.

Two Bear Capital is a venture capital firm founded in 2019 by Mike Goguen, a former Sequoia Capital investor. It backs early-stage companies combining life sciences and technology, including AI and machine learning, computational biology, drug discovery, diagnostics, quantum security and enterprise infrastructure. The firm pairs investment capital with scientific, technical, operating and company-building support. Its team includes investors, platform and operating specialists, research and finance staff, and an advisory network. It operates from Whitefish, Montana, with offices in Menlo Park, San Diego, Boston and New York. Its publicly listed portfolio includes Montara Therapeutics, Novoron, Abilita Therapeutics, Talus Bio, Revenium, Selector and TileDB. Two Bear co-led Montara's initial seed round in July 2024 and participated in its March 2025 seed expansion.

Vi Partners AG is an Altendorf, Switzerland venture-investment adviser backing early-stage technology and healthcare companies in Switzerland and Europe. Its official imprint identifies the AG and Swiss FinSA framework. Founded in2001 with ETH Zurich and Swiss corporate ecosystem support, the firm works through advised investment vehicles, including the historical corporate-backed evergreen Venture Incubator AG and newer venture funds. Its strategy spans B2B software, artificial intelligence, data infrastructure, fintech, industrial technology, biotech, medtech and digital health, generally at seed/SeriesA with a stated CHF2–4M initial-investment preference. The current directory publishes16 investment, operating, finance and advisory professionals. Its relevant portfolio includes cognitive-health company Altoida and molecular-discovery company Sibylla, alongside software and medical-technology businesses. Historical investments and financial affiliations are retained under existing canonical Investor3842. The2020-vintage fund completed an actual CHF75M first close inApril2020 and a later second close inJune2021 whose amount is not established in the reviewed own announcement. InJanuary2026 the firm announced a new fund’s first close, with capital amount undisclosed and a CHF150M target; the target is not treated as a completed fund size. Corporate backed evergreen vehicle capital, cumulative deployment and fund targets are distinguished from final LP closings. Founders’ individual angel track records and operating roles at other employers are distinct from manager investment participation.

3B Future Health Fund is a healthcare venture investment platform launched with Helsinn support in 2016 and rebranded from Helsinn Investment Fund in 2020. It backs early-stage scientific and therapeutic companies, particularly in oncology and rare diseases, across Europe, the US and Israel. Its deep-technology portfolio includes computational protein-folding discovery at Sibylla and precision diagnostics; Gain Therapeutics provides a neuroscience connection. Fund I was the Luxembourg Helsinn Investment Fund SA SICAR, subsequently called 3B Future Health Fund I. Fund II is 3B Future Health Fund II SCA SICAV-RAIF, managed by Luxembourg general partner 3B Future Health GP SARL and scientifically advised by Monaco-based 3B Future Health Ventures SARL, formerly Helsinn International Services. The 2021 launch also identifies Lemanik as the AIFM. These legal roles are distinct from the shared investment brand and Helsinn pharmaceutical operations. The current public directory names ten general partners and advisers. Two fund vehicles and their launch dates are verified, but final LP fundraising amounts remain undisclosed: the first fund’s stated USD 50 million future corporate commitment and reported Fund II targets are not treated as final capital raised. Its own portfolio distinguishes Fund I and Fund II, while transaction-specific financing links require issuer evidence.

Brewer Lane Ventures is a Boston-based early-stage venture investment firm focused on financial services, insurance and healthcare technology. Its own privacy/legal disclosures identify Brewer Lane Management LLC and affiliates as the investment-adviser firm; the2025 SEC FormADV identifies exact manager CRD307293/802-118153. General-partner titles on the directory are customary business titles and do not themselves establish individual legal general-partner status. The manager is separate from its named Delaware fund limited partnerships and fundGPs. The firm supports founders through insurance and financial-services operating experience, strategic relationships and go-to-market assistance. Its source-qualified portfolio includes AI underwriting, claims guidance, healthcare payments and financial-service infrastructure; manager testimonials and company performance claims are not independently audited results. Current published leadership consists of founder/managingpartner JohnKim, generalpartners ChrisDowner/RohanMalhotra/MarthaNotaras, strategicinvestmentlead JaeYoon, operatingpartners DavidCastellani/AdamCloud, financehead RonBucchi, seniorassociate KaitlinDerry and businessmanager CourtneyHowe. Eight separately listed external advisers cover technology strategy, enterprise software, assetmanagement, insurance, benefits and riskanalytics; they are not inferred operating employees or personal investors. Official FundI FormD filedApril22,2020 reportsUSD120M sold againstUSD200M offering, including sales fromDecember6,2019 throughJanuary7,2020 under separateexemptions. It is an actualsales snapshot rather than a verified finalclosingdate or200Mclose. For FundII, primarydealcounselAugust16,2023 reports an actual203Mfundformation close, while aNAICmemberprofile hostedbythemanager reports213M and aMarchclose. This sourceconflict is preserved; no arbitrarysinglefinalamount is asserted until the exactlegalvehicle amendment corroborates it, and amountsare notadded. FundII initial2022SECfiling establishesDelawareLP andseparateGP. LPportfolio carryingvalues, unfundedcommitments andfundtargets are notnewmanagerfundraisings. The retained manager identity and allsixexisting investmentrecords are preserved. Any new institutionalportfolio relationship requires a named actual source; quoted portfolio founders, advisers and managerpartners are not automatically individualcashbuyers.

Catalyst Investors is a New York growth equity firm founded in 1999 that backs technology companies moving from startup to expansion. It focuses on businesses with established product-market fit and typically at least $5 million of recurring revenue, providing expansion capital through primary and secondary transactions. Its AI, deep technology and neuroscience-related portfolio includes Corvus Robotics' autonomous warehouse systems, Sevaro's teleneurology services, Tava Health's mental-health platform and Ognomy Sleep's AI-enabled sleep-care platform. The current public team has 13 members, led by Managing Partner and Founder Brian Rich, Managing Partner Tyler Newton and Partner Kapil Desai; Ryan McNally is listed as Senior Advisor. Catalyst reports investing more than $1 billion in over 50 companies across five funds. It led Ognomy Sleep's $20 million Series A announced June 30, 2026. Its stated investment range of $10 million to $20 million or more describes typical checks and does not establish the size of any individual investment or fund.

Crystal Venture Partners is a New York early-stage venture firm investing at the intersection of insurance, risk and technology. Founded in 2022 by insurance operator Jonathan H. F. Crystal, it backs pre-seed and seed businesses, including AI underwriting, insurance distribution, disaster recovery and operational automation. Its typical USD1–3 million investment range is a published strategy guideline, rather than a confirmed individual company allocation. The current public team comprises Managing Partner Jonathan H. F. Crystal, Principal Stephen G. McGovern, Chief of Staff Cat Jordan and Associate Isabel Fields. The firm announced the final close of Crystal Venture Partners Fund I, L.P. on October 6, 2025 with USD33 million in committed capital from family offices and insurance companies. Its legal adviser is Crystal Venture Management, L.P., registered as an SEC exempt reporting adviser under CRD339641; the related general partner is Crystal Venture Partners GP I, LLC. Portfolio companies include Sixfold, WithCoverage, Bright Harbor, Novella and Gyde. The firm also separately identifies pre-fund investments, which are not automatically attributed to Fund I. Sixfold’s 2023 seed and 2024 Series A announcements identify Crystal as an institutional investor; a 2026 follow-on investment is not established by the reviewed sources.

Delos Capital is a life sciences investment firm founded in 2014 by Henry Chen, with investment and operating staff in Hong Kong, Cambridge and Taipei. It backs biotechnology and medical technology companies developing therapeutics, drug-discovery platforms and devices, with expertise spanning immunology, oncology, cardiovascular disease, neurology and rare diseases. Its portfolio includes computational-biology company TRexBio, gene-delivery developer STRM.BIO, RNA-targeting drug developer Rgenta, stroke-treatment company Imperative Care and neuromodulation developer Tulavi. Delos led TRexBio's USD84 million Series B announced in November 2024 and participated in its USD50 million Series B extension in January 2026. Its current public directory lists six investment professionals and five operations staff. The official portfolio groups investments under Funds I, II and III; fund sizes and closing dates require separate verified fundraising disclosures.

Magnetar Capital manages alternative-credit, quantitative and venture investment strategies. Its AI venture business backs companies developing foundation models, AI infrastructure and consumer or enterprise applications, and provides portfolio companies with access to dedicated GPU computing resources.

Monograph Capital is a transatlantic life sciences investment firm founded in 2021, with offices in London and San Francisco. It funds and helps build companies developing therapeutics, diagnostics, advanced biological manufacturing, digitally enabled healthcare and AI software for the life sciences industry. Its portfolio includes neurodegenerative gene therapy developer AviadoBio, depression therapeutics developer Autobahn Therapeutics, neuro-immunology company Sudo Biosciences, and AI platforms ODAIA and RegASK. Its team combines biomedical research, clinical medicine, investment and company-building experience. The UK advisory entity is Monograph Capital Advisors (UK) LLP, an appointed representative of FCA-regulated Odin Capital Management Ltd.

Mountain Group Partners is a Nashville venture capital firm that invests in early-stage human and animal life-sciences companies and disruptive technologies. Its life-sciences investments focus on diagnostics, medtech, precision medicine and selective drug development, while its technology strategy includes healthcare IT, business services and renewable energy. Partners draw on operating experience to help companies develop products and grow over long holding periods. Neuroscience examples in its published portfolio include Circular Genomics, which develops circular-RNA tests for neurological and psychiatric conditions, and Appello Pharmaceuticals, which develops mGlu4 positive allosteric modulators for Parkinson’s disease. Founded in 2002 with family-office roots, the firm says it remains the largest investor in its own funds.

Nascent is a proprietary, multi-strategy crypto investment firm launched in November2020. It combines early-stage venture investments with liquid strategies, protocol participation and in-house engineering and analytics. The founder’s launch statement describes capital supplied by team members themselves, rather than an outside-LP venture fund with a fixed lifespan; its current own professional profile describes permanent capital and more than fifty early-stage investments. Its technical portfolio includes decentralized AI consumer infrastructure, digital avatars, blockchain privacy and verification systems, smart-contract security, and post-quantum digital asset security. The public team lists co-founder Dan Elitzer, People and Performance leader Rebecca Peel, and venture partners Peter Shoemaker, Jessy and Brock Elmore. A separate primary professional biography identifies Josh Felker as a co-founder. Public staff and advisers are distinguished from personal investment attributions. Neither liquid holdings, portfolio-company financing nor a permanently invested proprietary capital base establishes a closed externally raised fund size. This nascent.xyz manager is distinct from water-treatment, corporate-software and similarly named financial businesses.

Pivotal bioVenture Partners is the US venture capital operation of Pivotal Life Sciences, established in 2017 and based in San Francisco with a Boston-area office. It invests in innovative therapeutics in North America and Europe, supporting company creation, private financing, IPOs and follow-on public-market financing. Current official biographies name Peter Bisgaard and Rob Hopfner as managing partners, Jeni Lee as a partner and Glenn Batchelder as a venture partner. Its portfolio includes neuroscience businesses such as Karuna Therapeutics and MapLight Therapeutics as well as other biotechnology companies. Fund I was announced in March 2017 at approximately USD300 million with backing from Nan Fung Group. Fund II closed on December 18, 2023 with USD389 million in commitments, bringing the partnership's aggregate commitments to USD689 million. The US operation is distinct from Pivotal bioVenture Partners China, Nan Fung Life Sciences and the broader Pivotal Life Sciences investment platform; the displayed wordmark is the official shared platform brand.

Polaris Innovation Fund is the specialist early-stage biomedical company-building programme advised by LS Polaris Innovation Fund Management, L.L.C., separate from the main Polaris Partners and Growth fund advisers. The retained historical LS Polaris investment identity represents this specialist adviser and its fund mandate. Current April8,2026 legal disclosures name two specialized affiliate vehicles: LS Polaris Innovation Fund, L.P. and Polaris Innovation Fund II, L.P. The original LS fund was formed in2017; an April2,2019 SEC exempt-reporting-adviser final filing identifies historical CRD290691, rather than establishing current standalone SEC registration. Current own legal disclosures independently confirm the adviser identity. The programme supports early academic research and active company creation across therapeutic platforms, diagnostics, life-science tools and healthcare technologies. Its current published eight-member directory includes six investment professionals and two scientific advisory committee members; outside MIT appointments are advisory affiliations, not presumed fund employment. Relevant published specialist portfolio includes ALS therapeutics company QurAlis, neurology-focused Muna, gut-brain-axis Kallyope, Alzheimer and other neurological diagnostic developer SunBird Bio, teen mental-health BeMe, Oui and Sesh, AI/CRISPR drug-discovery Engine Biosciences and conversational AI medication-management UpDoc. Portfolio listings include historical/exited companies and do not establish current operating status, actual cash allocation or financing stage. The two real specialist fund vehicles are recorded with undisclosed capital and close date; no gross assets, insurance LP carrying value, target or main Polaris fund close is treated as cash raised by these vehicles. Existing two legacy institutional checks remain preserved; the main platform Investor3220 remains separate and is not given a duplicate specialist allocation.

RiverVest Venture Partners invests in and helps build early-stage biopharmaceutical and medical-device companies addressing unmet patient needs. It leads financing rounds, forms companies, recruits management teams and supports clinical development and regulatory strategy. Its investments include conditionally active biologics, RNA therapies for neurodegenerative disease, rare-disease medicines, diagnostics and medical devices, with an emphasis on products that have a path to clinical validation and approval.

Samsara BioCapital is a Palo Alto biotechnology investment platform led by founder Srinivas (Srini) Akkaraju. The legal investment adviser is Samsara BioCapital, LLC, CRD288114/SEC801-113741, distinct from its investment partnerships and their general partners. Its2017launch fund invests in therapeutic innovation and company creation; the current public team also includes public-biotechnology investors, scientific venture partners, operating specialists and administrative staff. Scientific expertise covers drug discovery, gene therapy, neurosciences, computational biology and translational medicine. The current official directory names39people with separate role capacities. The Delaware Samsara BioCapital, LP master fund, CIK1699737, disclosed USD310,090,000 fully sold under its2018RegD offering; separate RegS commitments were excluded, so that amount is not an invented worldwide aggregate. Later fund gross assets are not new subscriptions. The2025Samsara Opportunity Fund, LP separately disclosed97,971,334USD initially sold against a200Mtarget; its final close and full size remain unpublished. The Cayman SMSR B1, LP feeder and the master-fund cross-reference use differing private-fund identifiers in the latest ADV, which is flagged rather than merged blindly. This biotechnology investor is distinct from Samsara’s listed IoT business, Samsara Eco and portfolio company Samsara Therapeutics.

Sherpa Healthcare Partners (夏尔巴投资) is a healthcare venture platform founded in 2018, investing in early and growth-stage biotechnology, gene technology, medical devices, diagnostics and healthcare services, primarily in Greater China and selectively in the United States. Its founders previously built Legend Capital’s healthcare investment team; their earlier investments are historical individual/team experience rather than automatically Sherpa fund investments. The current official directory lists managing partners Xiangyu Ouyang, Daqing (Darren) Cai and Cheng Xing. Raymond W. Cohen was appointed venture partner in January 2025, corroborated by his current company biography. Legal adviser entities include Cayman Sherpa Healthcare Partners Co., Ltd. (CRD306831, SEC802-118582) and China’s Zhuhai Sherpa Equity Investment Management Company Limited (CRD308824, SEC802-118655); fund GPs are separately identified in their filings. These are exempt reporting adviser records, not a claim of SEC registration. Fund I and Fund II completed oversubscribed closes announced in July 2020 and July 2021, respectively, but their final amounts and exact closing days are unpublished in the reviewed primary releases. A distinct Cayman co-investment fund is documented. The team’s historical managed-capital and portfolio totals are not cash closes or the platform’s individual investment allocations. Sherpa is distinct from US Sherpa Capital/ACME, Spanish Sherpa Capital, Sherpalo Ventures and companies using the Sherpa name.

Tekla Capital Management LLC was a Boston-based specialist healthcare investment adviser, registered historically under SEC CIK1300336 and Delaware EIN01-0628853. Its platform invested across public and private biotechnology, medical devices, diagnostics, life-science tools, healthcare services and information technology, including neuroscience companies such as Arkuda. A 2017 manager presentation documents a 2002 management buyout of Hambrecht & Quist Capital Management from JPMorgan and the 2012 adoption of the Tekla name; the predecessor’s fund history is not the present LLC founding date. On October 27, 2023, distinct legal adviser abrdn Inc. assumed the four funds’ advisory agreements through an asset/capabilities transfer. This is not evidence that Tekla LLC renamed itself abrdn or that every Aberdeen group investment belongs to historical Tekla. The continuing listed closed-end funds are abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW), formerly Tekla-branded. The historical team recorded here is dated to the underlying 2017/2023 manager publications; it is not a current independent Tekla employee directory. Jason Akus became lead portfolio manager in June 2024; Daniel Omstead’s announced advisory transition ran through September 2024. Current healthcare-team biographies and fund pages corroborate the succeeding investment operation and its healthcare AI research. Fund net assets, managed assets, acquisition consideration and proposed vehicle targets are not fund cash closes. Specific issuer participation by funds managed by Tekla is represented separately from personal director holdings and unallocated fund subscriptions.

The Invus Group LLC is the New York legal investment manager within Invus, a global investment platform founded by Raymond Debbane in1985. Invus partners with founders and management teams using long-term, continuous capital supplied by the European family group Artal, rather than forcing investment exits to follow a limited-life fund timetable. Its private equity activities involve minority or majority stakes and operational support; public-equity investing began in2004 and includes joint private biotechnology investments with the life-sciences team. The current website reports overUSD10B under management, a compounded capital pool, not a newly closed fund or fresh cash raise. The exactUS entity is confirmed by the own legal disclaimer, contact page and July29,2026 SEC umbrella adviser filing: Invus Financial Advisors LLC CRD161603 is filing adviser and The Invus Group LLC is a relying adviser. Invus S.A.S., Invus Asia Limited and Invus Singapore PteLtd are separately named local entities. Invus Opportunities, launched2007, is a distinct technology investing unit with retainedInvestor5700; its checks are not transferred to the main retained3736 record. Invus Financial Advisors and Avicenna are also source-qualified affiliates, not automatically the main company’s buyer allocation. The current global directory publishes92 people:79 main private/public equity or administration personnel plus13 explicitly labelled Opportunities/Financial Advisors affiliate entries. All affiliation labels are retained; a unit-specific title is not asserted as a general platform investment role. It supplies84 genuine named original portraits and eight anonymous silhouettes; silhouettes are not used as personal profile photos. Current President and CEO Raymond Debbane is also ArtalCEO, while Philip Bafundo is CFO and CCO of the main group. The official filing identifies Bermuda Invus LP as a private investment vehicle managed by The Invus Group LLC through Invus Advisors LLC. Its reported gross asset value is a valuation snapshot, not subscription cash or a completed capital close, so fund size and closing day remain undisclosed. Other InvOpps, IFA and Avicenna funds in the umbrella filing are audited separately and not silently assigned to the main manager. Historical and personal partner holdings, family capital and group AUM remain separate from source-proven institutional financing participations. The13 existing investment links are preserved. InJanuary2023 Stanford University publicly announced a collaboration in which Invus funded two glioblastoma drug-prototype research projects, with contingent intellectual-property options and possible future spinouts. This is a research collaboration with unpublished funding size, not an identified startup equity round or approved therapy.

San Francisco-based early-stage venture firm founded in 2022 that invests in technology supporting health, mental wellbeing and human connection. Its second fund focuses on companies using AI to improve health, wellness and resilience, typically investing $1 million to $5 million. The firm supports founders through community and wellbeing programs alongside investment advice. Fund II closed at $77.7 million in May 2026; its portfolio spans AI, biotechnology, care delivery and consumer wellbeing.

Science-driven venture capital firm investing in biotechnology, TechBio and medical technology. Its published portfolio spans AI medical imaging, neuropsychiatric and neurorestorative therapeutics, condensate biology, targeted protein degradation, gene therapy and precision diagnostics. Named portfolio companies include Subtle Medical, ProNovo Therapeutics, Myrobalan Therapeutics, Neural Galaxy, Dewpoint Therapeutics and Twist Bioscience.

Arkin Bio Ventures is Arkin Capital’s early-stage biotechnology venture investment platform, distinct from the later clinical-stage Arkin Bio Capital fund. It supports preclinical and early clinical companies and lists three fund generations: Arkin Bio Ventures I, II and III. Pini Orbach oversees the funds as managing partner. Adar Makovski Silverstein and Avital Adler are principals on the third fund’s management team. Investments in neuroscience, including chemogenetic gene-therapy developer Redpin Therapeutics, are described in the manager’s portfolio; their exact financing records remain under review. Two previously imported HI-Bio Series B links have been corrected to Arkin Bio Capital, the participant named in HI-Bio’s original financing announcement.

Builders VC is the venture investment firm operating through Builders VC LLC, SEC CRD288444 / exempt reporting adviser802-110700, headquartered at601 California Street, Suite700, San Francisco. Its March2025 FormADV confirms the exact legal adviser and address. This profile is distinct from Builders Vision, similarly named construction/AI companies and unrelated Builders Fund managers. Hawaii Technology Development Corporation’s2025 official fund diligence states that the firm was formed in2016. Builders backs founders modernizing complex legacy industries including healthcare, agriculture, real assets, industrials and enterprise software. Current own portfolio products include AI wastewater treatment, behavioral healthcare, synthetic biology, robotics and industrial automation. Its proprietary BLOX sourcing engine is described in government diligence as applying machine learning to source early companies. Portfolio product capabilities and investment performance remain publisher claims, not independent validation. The current own public directory names26 people:11 core investing,6 portfolio support,2 operations and7 sector/geographic venture partners. Partner and venture-partner categories are preserved rather than assuming every adviser is a salaried employee. Native biography pages give individual experience. Three repeated publisher pictures attached to different people are rejected as identity-verified portraits. Primary government diligence datedApril24,2025 reports FundI171M and FundII250M capital raised, and350M raised towards a400M FundIII target. FundIII’s2024 SEC initial filing had zero sold; that historical snapshot does not negate the later capital reported. Final close dates remain undisclosed. The Hawaii-specific fund’s proposed10M first close and government5M recommendation are targets/recommendations, not proof of completed cash closing. Legal entrepreneurs vehicles remain separate, without invented allocation or summing parallel structures.

Cambridge Enterprise is the University of Cambridge’s commercialisation and early-stage investment subsidiary, legally Cambridge Enterprise Limited, England and Wales company01069886. It supports technology licensing, academic consultancy, venture creation and investments in research spinouts, including AI, deep technology, biotechnology and neuroscience. Cambridge Enterprise Ventures is its internal investment team, formerly Seed Funds, rather than a separately proved external manager or the entire university. Companies House records the legal company’s incorporation on5September1972 and previous name Lynxvale Limited; the university describes its present wholly owned commercialisation structure as established1December2006. These dates describe different legal and operational milestones. Separate subsidiary Cambridge University Technical Services Limited05749230 handles consultancy contracts and has no employees of its own. The directory’s published operating, support, entrepreneurial and board affiliations are scoped to Cambridge Enterprise. Three university evergreen seed funds recycle returns, and the Technology Investment Fund is an internal proof-of-concept programme. University of Cambridge Enterprise Fund EIS series are managed by Parkwalk Advisors in conjunction with Cambridge Enterprise; these partner mandates are distinguished from the internal evergreen funds. Cumulative investment, portfolio values, project commitments and university budget announcements are not represented as external LP fund closes. Primary issuer financing identifies Cambridge Enterprise Ventures as a participant in TRIMTECH’s March2025 seed; existing recipient checks and personal attributions are preserved.

Cambridge Innovation Capital (CIC) is a Cambridge venture investment platform backing deep technology and life sciences, including artificial intelligence, quantum computing, photonics, semiconductors, robotics, genomics, gene therapy and neuroscience. It has a close relationship with the University of Cambridge and supports companies emerging from the regional research ecosystem. The website operator/parent Cambridge Innovation Capital Limited, company08243718, was incorporated October8,2012 and formerly used PLC; the distinct regulated subsidiary Cambridge Innovation Capital Manager Limited, company12002307, was incorporated May17,2019 and is FCA-authorised under FRN918898. This retained investor profile represents the published CIC investment platform, with legal parent and manager distinguished rather than treating every group entity as a cash subscriber. Its published team includes investment and operating staff, board directors, an advisory panel, specialist advisers, and current or explicitly former entrepreneurs in residence. FundII raised GBP225M in2022; its USD300M equivalent is not a second raise. The GBP100M Opportunity Fund was launched inFebruary2025 with primary-confirmed GBP20M British Patient Capital commitment and GBP15M Aviva investment; a final GBP100M cash close is not asserted. Legacy FundI emerged from corporate shareholder capital, with cumulative commitments and actual capital calls distinguished from a traditional external LP closing. AUM, portfolio co-investment and fund management transfers are not fresh closed cash. Existing institutional and individual investment records are preserved.

ClavystBio is a Singapore life-sciences investor and venture builder established by Temasek in 2022. Its legal website entity is ClavystBio Pte Ltd, Singapore registration202027056H; the operational launch year is distinct from the earlier incorporated legal entity. It invests in and helps build therapeutics, medtech and digital-health companies, supports commercialization partnerships, and operates Node1 laboratory and collaboration space at Singapore Science Park. Its mission connects scientific innovators with company-building expertise and international capital. The current public directory names21 operating team members, six board members including the chief executive, and three advisers:29 unique people. Current CEO Khoo Shih and CFO Kang Lin Ong lead the platform. Current published directors and advisers differ from the historical2023 launch roster; historical outside affiliations are not asserted as present roles without current evidence. The October2023 launch publication reported more thanUSD220M committed to companies and external early-stage venture funds. That aggregate commitment is not paid-in cash, a completed proprietary fund close, or a new company funding round. The current own portfolio lists16 companies and five separate fund-manager partners; external partners are not ClavystBio-managed fund vehicles. The platform also participates in65LAB, a research translation and venture-creation collaboration; project awards and partnership budgets are not inferred equity checks. Existing Sunbird Bio, Paratus Sciences and Virtual Therapeutics Corp investment records and their attribution are preserved. In particular, the May24,2024 Virtual Therapeutics minority investment remains separate from its subsequent Akili acquisition. Public sources reviewed do not disclose a separately closed ClavystBio-branded fund or complete subscription allocations.

Cormorant Asset Management, LP is a Boston-based life-sciences and healthcare investment adviser founded by Bihua Chen in 2013. It invests in private and public biotechnology companies using fundamental research into drugs, technologies, therapeutic biology, business models and competition. Its own current roster includes scientific-investment leadership and trading, finance, legal, compliance, investor-relations, analytics and data-operations staff. SEC Form ADV dated May 27, 2026 confirms the exact legal adviser, CRD167820/SEC801-79513, and seven master investment vehicles with eight feeder vehicles. The private healthcare series I–VI and global healthcare master/feeder structure remain distinct legal vehicles. Fund VI’s November 25, 2025 Form D reports USD75.2 million actually sold by the domestic issuer alone; this is a sales snapshot, while USD400 million is the combined domestic/offshore offering target. Regulatory assets under management, fund gross assets and public-equity 13F holdings are not fundraising closes or new company checks. Neuroscience relevance includes primary-source neurodegeneration financings and managing director Raymond J. Kelleher’s clinical neurology and research background. Arkuda’s issuer separately names Cormorant as a co-lead of its February 10, 2022 USD64 million Series B; no individual investor ticket or fund allocation is inferred.

Eli Lilly and Company (NYSE: LLY) is an Indiana-incorporated global biopharmaceutical company founded in 1876 and headquartered at Lilly Corporate Center in Indianapolis. It develops and manufactures medicines across cardiometabolic health, immunology, oncology and neuroscience. Its neuroscience business includes Alzheimer’s disease, migraine and research into neurological disorders, psychiatry and pain. Kisunla (donanemab-azbt) received US FDA approval in July2024 for Alzheimer’s disease, with treatment studied and initiated in the mild cognitive impairment or mild dementia population; that product-specific authorization is not a blanket approval of other investigational medicines or AI systems. Lilly uses AI and data science in drug discovery and offers drug-discovery models through TuneLab. Its Catalyze360 platform comprises the global Lilly Ventures investment arm, Gateway Labs, ExploR&D and TuneLab. Corporate business development separately covers partnering, licensing, direct equity investments, acquisitions and alliance management. The current published roster includes its global board and executive committee plus named corporate-partnering and innovation-program contacts. David Ricks is chair and CEO; Carole Ho leads Lilly Neuroscience, Daniel Skovronsky leads research and product development, and Jacob Van Naarden leads oncology and corporate business development. This profile is the legal corporate parent; the distinct Lilly Asia Ventures manager and other legacy Lilly-named investment records are preserved separately. Borrowing proceeds, commercial collaborations, research partnerships, manufacturing commitments and market value are distinct financial concepts; prospective milestones or credit limits are not treated as completed investment checks.

Gates Foundation is the Seattle-based U.S. private charitable foundation historically named Bill & Melinda Gates Foundation. Its present operating legal entity has EIN56-2618866 and arose from the2006 foundation/trust restructuring; its philanthropic history dates to2000. The2024 Form990-PF Statement33 records the legal rename effectiveJanuary6,2025 with the same EIN. It funds global health, maternal and child health, infectious-disease research, poverty reduction, education and gender equality through grants and charitable investments. Its Strategic Investment Fund (SIF), formerly the Program-Related Investments team untilAugust2018, uses direct equity, debt, guarantees and other financial tools to advance charitable goals and recycle returns. SIF is an internal impact-investing program, not a separately verified LP fund. Its publishedUSD2.5B mandate/budget is not a new external fund close; planned charitable spending and endowment values are also separate from investment closes. Relevant portfolio activities include AI-assisted diagnostics, proteomics, life-science tools, biotechnology, digital health and education. Bill Gates is chair and Mark Suzman CEO; the foundation plans to closeDecember31,2045. The Gates Foundation Trust holds the separate endowment, managed independently by Cascade Asset Management; foundation staff have no influence over Trust investing. Historical foundation investments must not be reassigned to the Trust from name similarity. Legacy BillMelindaGatesFoundation3594 and all references remain preserved as a separate historical-name record pending any explicit consolidation.

Illumina Ventures is an independently managed venture investor focused on genomics, precision health, life-science tools, diagnostics, therapeutic platforms and related digital-health and planetary-health applications. Nicholas (Nick) Naclerio founded the firm in 2016. Its legal manager is IIF Management Company, LLC (CRD 283782; SEC exempt reporting adviser file 802-107904), headquartered in Foster City, California. It operates separately from Illumina Inc., the sequencing company and strategic anchor investor in its funds. The current public team includes investment professionals, scientists, US and UK laboratory staff, venture partners, external advisers and operations staff. Chief AI Scientist Martin Moorhead contributes expertise in machine learning, computational biology and genomics. The published portfolio includes AI drug-discovery companies Iambic Therapeutics and DeepSeq.AI, AI and automation platform Bullseye Biosciences, and machine-learning company Integrated Biosciences. Encoded Therapeutics and Kallyope establish genetic-medicine and neuroscience relevance. These investment themes do not establish regulatory approval or clinical efficacy for investigational portfolio products. The firm manages the legally separate Illumina Innovation Funds I, II and III. Fund I announced a $230 million close on October 16, 2017; Fund II announced a $325 million close on September 20, 2021. Fund III reported $60 million sold in its August 29, 2025 Form D amendment; that disclosed partial raise is distinct from its $200 million offering target and an unverified final close. Current fund asset values and earlier aggregate capital-under-management figures are not additional cash raised. Alamar Biosciences investments are attributed to the actual participating fund vehicles under this manager, preserving their distinctions from corporate Illumina and personal investments.

Jeito Capital is an independent biopharma investment manager founded by physician-scientist Rafaèle Tordjman in2018, with a continuous-financing strategy supporting clinical-stage therapeutics through development and commercialization. The exact legal manager is Jeito Capital SAS, RCS Paris839611449/VATFR51839611449, authorised by the French AMF underGP-19000043. Its Paris-led multidisciplinary public team spans investment, clinical/translational science, regulatory, commercial, talent and operating functions, with London investment leadership. Neuroscience and neuromuscular exposure includes Noema and Augustine Therapeutics. Current public English directory names32 people, including external finance adviser AlainRougon; biographies not on current directory do not imply present employment. JeitoI closed EUR534M announcedSeptember20,2021. JeitoII final-close March31,2026 was above EUR1B, announcedApril8,2026; exact undisclosed total remainsNULL rather than being inferred from target or FX-rounded USD1.2B. Reported EUR1.6B AUM is not another fund or cash close. Existing investments, fund references, shared people and personal attribution are preserved.

Cell-therapy operating company within Gilead Sciences. Corporate investment participation does not identify a standalone venture capital firm.

LifeForce Capital is a healthcare venture-capital manager investing in software businesses that reshape care delivery and in software-first technology platforms for therapeutic development. Its own portfolio includes AI-enabled discovery, clinical software, precision neuroscience and technology-assisted care. The legal adviser is LifeForce Capital Management LLC, CRD 282550 and SEC file 802-118500, an exempt reporting adviser; that status does not imply SEC registration or endorsement. Its March 18, 2026 filing identifies John Kenneth Noonan as managing director and owner and lists a Chevy Chase, Maryland principal office, alongside historical San Francisco affiliations. The public roster is scoped to six named affiliates supported by the adviser filing, issuer disclosures and their own published biographies. Adam Pelavin co-leads AI-plus-health and neuroscience strategies; Jamie Daves publishes a venture-partner affiliation and co-founded the Neurorights Foundation. Sander Duncan and Rishi Sikka have dated or explicitly historical LifeForce roles. Nathan Bays is a FINRA-disclosed part-time venture advisor. The manager does not publish a complete accessible current staff directory, so these records are not represented as its entire current payroll. Sixteen exact legal private-fund vehicles are disclosed in the 2026 adviser filing. Their existence and management relationship do not establish new cash closings. Initial Fund I and II filings reported no securities sold against fundraising targets, which are not recorded as capital raised. Underlying fund or SPV allocations are not inferred from portfolio brand mentions. Synapticure’s February 2022 launch describes an actual USD 6M seed closed in early fall 2021 with LifeForce participating; that issuer participation is maintained separately from personal advisers and other corporate entities.

Longwood Fund is a Boston-based life sciences venture capital firm founded in 2010 that builds biotechnology companies and invests in therapeutics from early company formation through clinical development. Its team combines venture investing, scientific diligence, company creation and operating support, with dedicated early-stage and growth-stage investment activity. Its neuroscience portfolio includes Newleos Therapeutics, Engrail Therapeutics and Progentos Therapeutics. The current public directory lists 16 staff and venture partners, supported by 20 living members of a Strategic Advisory Board. Christoph Westphal is co-founder and general partner; Rich Aldrich is co-founder and partner. In May 2023, Longwood announced USD180 million committed to its sixth fund and related vehicles; its July 2020 fifth-fund announcement reported approximately USD170 million including two related incubator funds. These are aggregate commitments, with individual legal fund sizes not separately disclosed in those announcements.

European venture capital firm backing technology companies in critical industries, with a focus on the compute and energy stack, security, financial technology and systems for the physical economy. Magnetic supports founders from the earliest stages through long-term partnerships. Founded and led by David Rosskamp, the Berlin-based firm has confirmed investments in NaroIQ and Project Eaden. Its website also features selected early partnerships with companies including Trawa, TYTAN Technologies, SimScale, Mabyduck, Statespace and Imandra; those partnerships span the team’s work over the past decade and are not all established investments by a single current Magnetic fund. This firm is separate from US life-sciences investor Magnetic Ventures. Its legal manager is Magnetic Management GmbH, with a registered address in Hamburg.

Mass General Brigham Ventures is the venture-investment business associated with the Mass General Brigham nonprofit academic healthcare system. Founded in 2008, it supports company creation and seed and early-stage life-sciences businesses, with follow-on investment through later development. Its focus includes therapeutics, medical devices, diagnostics and digital health, including precision neurology, mental health and clinical technology. The legal adviser is Mass General Brigham Ventures LLC, an exempt reporting adviser (CRD286361; SEC802-108906), formerly Partners Innovation Management Co. LLC and also using the Partners Innovation Fund name. These adviser aliases do not make each separately named legal fund the same entity. The current primary directory publishes eight investment-team members, three entrepreneurs in residence and eleven alumni entrepreneurs in residence. Alumni affiliations are historical; exact terms are unpublished. The March17,2026 ADV identifies Partners Innovation Fund LLC, Partners Innovation Fund II LP and Mass General Brigham Fund III LP. Regulatory gross asset values and manager assets under management are distinguished from actual fund closes. The healthcare system’s separate AI and Digital Innovation Fund and Amplify translational programs are not assumed to be external LP venture funds managed by this adviser. The manager’s current portfolio includes QurAlis, Nocion Therapeutics, InStride Health, Violet Therapeutics and other science-based companies; its historical portfolio includes neurodegeneration and hearing-loss companies. Portfolio evidence establishes institutional investment but does not disclose each cash ticket or financing date. The preserved historical organization identifier and all existing investment links remain associated with this same manager.

Omega Funds is a life-sciences investment platform founded in 2004 by Otello Stampacchia, with published offices in Boston and Geneva. Its own legal notices and SEC records identify the US adviser as Omega Fund Management, LLC, CRD157753/SEC801-74224. It creates and finances biotechnology and medical-technology companies from formation through clinical development and public markets, including neuroscience, neurovascular intervention and precision medicine. Its current public directory identifies 28 investment, management, venture-advisory and operational people; these are published affiliations rather than total employee headcount. Fund-specific legal partnerships remain separate from the manager and subscribing vehicle allocations are not inferred from platform-level investment announcements. Original primary disclosures substantiate Fund V USD300M fully sold, Fund VI USD438M closed, Fund VII USD650M closed and Fund VIII USD647M closed. Fund IV has an older partial-sales disclosure and an explicitly unknown final corpus. SEC public securities holdings and aggregate fundraising are not treated as fund closes. Genuine original publisher logo and portraits are used; shared company-board records and all inherited investments are preserved.

Oxford Science Enterprises plc is an independent investment company and venture builder that creates, funds and develops companies emerging from University of Oxford research. Its focus spans deep tech, life sciences and health technology, including quantum computing, artificial intelligence, photonics, biomedical engineering and therapeutics. Its patient-capital model supports ventures from formation through growth. The operating platform began in 2015; its legal company09093331 was incorporated on19June2014 and was formerly Oxford Sciences Innovation plc until September2021. OSE Manager Limited is a separate wholly owned regulated subsidiary. The public directory includes executives, investment teams, central staff, entrepreneurs and scientists in residence, advisers and non-executive directors; those affiliations are distinguished by their published titles. Corporate equity raised, portfolio value, cumulative co-investment and net asset value are not represented as new LP fund closes. Complete portfolio transaction history and separate regulated-subsidiary identity remain under audit.

Pfizer Ventures is the corporate venture-investing unit of Pfizer Inc., established in2004. The existing venture-manager profile is distinct from the separately retained Pfizer operating-company profile; a PfizerVentures attribution identifies the investing programme and does not assert an undisclosed fund/SPV or exact contractual subsidiary payer. Pfizer’s2018 expansion consolidated the former PfizerVentureInvestments group and R&DInnovate equity-investing activity into this programme. It operates through Pfizer’s Worldwide Business Development organisation, investing equity alongside other investors and supporting portfolio companies with scientific, strategic and board involvement. The current primary directory publishes twelve people, led by MichaelC.Diem as VicePresidentWWBD/SeniorManagingPartner, across investment, scientific, legal, finance and executive-assistant responsibilities. DenisPatrick is additionally retained with his2025newsletter ManagingPartner affiliation, qualified because the live2026directory omits him. Historical leadership such as BarbaraDalton in older newsletters is not used to override the current roster. Published portfolio-company board roles and personal careers do not imply individual cash investments. Current areas of interest include oncology, inflammation/immunology, cardiovascular, metabolic/obesity, vaccines and platform technologies. The2025newsletter specifically describes AI-driven antigen mapping at CartographyBiosciences and machine-learning-informed drug design at Enodia, alongside TRIMTECH protein-degradation approaches for neurodegenerative disease. The2018 primary expansion articulated a neuroscience investment strategy and named Aquinnah,Autifony,Cortexyme,MindImmune,Mission andNeuronetics. Arkuda’s actual2019/2022 financing announcements separately identify PfizerVentures’ institution-level checks in neurodegenerative-therapy development. These are research/investment facts rather than clinical-efficacy or regulatory-approval claims. Pfizer’s2018 USD600M commitment was corporate venture-capital allocation, with approximately25%/USD150M planned for neuroscience; it is not an independently verified closed LP fund. The approximatelyUSD500M historically invested and overUSD1B reported assets under management are different metrics. Likewise2025portfolio aggregate financings of roughlyUSD1B and strategic transactions of roughlyUSD4.5B are portfolio-company activity, not capital raised by this unit. The2025report describes a China venture vehicle with an unnamed local VC partner but does not establish its legal name, manager or cash close. No LP vehicles or fund cash closes are fabricated. The authentic Pfizer corporate mark is the same brand used in the unit’s own current newsletter, not an invented separate logo.

Pivotal Life Sciences is a global healthcare investment platform backing companies developing medicines and biomedical technologies for substantial unmet medical needs. It combines the US Pivotal bioVenture Partners venture operation, a China venture-building operation and a public-equity strategy spanning company creation through listed biotechnology businesses. Its investment and operating teams work in San Francisco, the Boston area, Shanghai and Hong Kong. Pivotal also employs data science, machine learning and software specialists to support biotechnology investment research. Vincent Cheung chairs the platform; Peter Bisgaard and Rob Hopfner are managing directors. Nan Fung Life Sciences is a parent organization, rather than an interchangeable name for the US venture partnership or its individual funds. The platform was a named investor in Engrail Therapeutics' March 2024 Series B. The US venture partnership's second fund closed at USD389 million in December 2023; aggregate commitments to that partnership were USD689 million at the time. These partnership figures are distinct from the wider platform's reported assets under management.

Sanofi Ventures is Sanofi’s corporate venture investment arm, backing biotechnology, AI and digital-health companies globally from seed through later private rounds and IPO participation. Its evergreen strategy focuses on immunology, rare diseases, neurology and vaccines, while supporting companies with board involvement and access to Sanofi’s scientific, clinical, regulatory, manufacturing and commercial capabilities. Sanofi announced an additional $625 million multi-year commitment on September 24, 2025, bringing reported assets under management above $1.4 billion; this was corporate evergreen funding, rather than a separately closed external LP fund.

European venture capital firm investing in healthcare and sustainability from Paris, London and Milan. Its life-sciences strategies support company creation, early-stage biotechnology, medical devices, digital medicine, industrial biotechnology and later-stage crossover investing. The Biovelocita accelerator works with European research institutes to create and develop new biotech companies, including Alzheimer’s therapies and advanced cancer cell therapies.

Surveyor Capital is a fundamental equities investment unit of Citadel, founded in 2008. Its sector-aligned teams combine long/short investing and equity capital markets with Citadel’s market-neutral risk framework. Its current primary website names healthcare, technology/media/telecommunications, industrials, energy, consumer and financials, with offices in Chicago, Dallas, Greenwich, Miami and New York. The site reports more than110 investment professionals as of July2026; it does not publish a complete named staff directory. Head Phillip Lee is current-directory verified; additional published staff features and historical roles are explicitly dated. Surveyor also participates in private biotechnology financings, including neurodegenerative-disease programmes at Arkuda and inherited CNS-biotechnology portfolio exposure. It is a Citadel unit rather than a standalone venture partnership. The profile uses the authentic Citadel corporate brand displayed on Surveyor’s own site; no separate Surveyor logo has been verified. A historical SEC filing identifies Surveyor Capital Ltd. as a Cayman investment fund legally managed by Citadel Advisors LLC. The official LEI registry now lists that vehicle as Citadel Multi-Strategy Equities Master Fund Ltd., with Surveyor Capital Ltd. as its previous legal name. That fund-name bridge does not rename the current Surveyor business or identify the exact legal subscriber of each private-company transaction. No capital allocation, assets under management or unverified external fundraise is recorded as closed cash.

The Vertical Group is a healthcare venture-capital firm focused on medical technology and biotechnology. Its own history states it became independent in 1988 as successor to the venture-capital division of F. Eberstadt & Co.; some external biographies use 1989, so 1988 reflects the firm’s published independence date. The firm invests from company formation through later growth and has incubated medical-device businesses, with offices published in New Jersey and San Mateo, California. Its partners combine investing, law, cardiology and operating experience. Its public partner directory names Richard B. Emmitt, John E. Runnells, Jack W. Lasersohn and Tony M. Chou as general partners. The directory contains historical company affiliations and older development-stage descriptions; these are not represented as current independent company boards or current clinical status. Recent issuer financing releases verify investments in cognitive-rehabilitation company ReEmerge, VR visual-therapy developer Luminopia and stroke-device company Route92 Medical. The older portfolio directory identifies investments in neurosurgical technology, stroke therapeutics, digital health and medical devices, including Monteris Medical, Remedy Pharmaceuticals, Omada Health, Outset Medical and Silk Road Medical. Legal fund names Vertical Fund I LP and Vertical Fund II LP are verified by the firm’s own disclaimer, but public actual cash-close totals and exact dates remain unverified. The Vertical Group is distinct from Vertical Venture Partners, the Nordic Vertical healthcare consultancy and Vertical Group investment bank. A legacy ONI attribution was corrected after full primary-source identity and protected-reference audits: the original participation record now names the distinct Vertical Venture Partners, as stated by ONI. The Vertical Group’s verified healthcare financing relationships are preserved.

Versant Ventures is a global biotechnology venture investor and company-creation platform, founded in1999. The exact adviser and website operator is Versant Venture Management, LLC, SEC exempt-reporting adviser CRD161130/802-75823, with Canadian and Swiss affiliates explicitly qualified in its legal disclosures. It backs therapeutics, including neuroscience, gene and cell therapies, computational and AI-enabled discovery; its Discovery Engines build companies with academic founders and in-house scientific teams. Current public directory lists36 investment, operating, resident, finance/legal and advisory people. Neuroscience relationships include Capsida, Inception and Biotie; artificial intelligence exposure includes published ML-enabled small-molecule discovery work. Website AUM USD5.5B is a portfolio-management metric, not a closed fund or cash round. Primary closed commitments are represented by distinct FundV, VI, VII, VIII, VoyageursI/II and VantageII vehicles, with regulator-qualified actual FundIX sold commitments; Canadian/parallel/feeder vehicles are not added again to combined family totals. Existing historical checks, roles, personal attribution and protected references are preserved. Distinct Versant media and software businesses are not merged.

Westlake BioPartners, historically Westlake Village BioPartners, is a Los Angeles-area life-sciences venture platform co-founded in 2018 by Beth Seidenberg and Sean Harper. Its legal adviser is Westlake BioPartners, LLC, CRD 299325 / SEC 802-114322, an active exempt reporting adviser. The firm combines scientific evaluation, translational development and operating support to build therapies for serious disease, including gene therapy, neurological and neuroimmune disorders, and pain. Its current official directory lists nine investment and operating professionals. David Allison and Mira Chaurushiya joined Beth in the managing-director team in 2023; Sean Harper is a historical co-founder whose current role is not established by the directory. Its Delaware funds comprise flagship Funds I, II and III plus a separate Opportunity Fund I. Verified announced commitments are $320 million for the inaugural fund, $430 million for Fund II, $70 million for Opportunity Fund I and $450 million for Fund III. Exact final closing days are unpublished. The 2020 $500 million headline combines Fund II and Opportunity Fund I, while the 2023 $1.3 billion headline is cumulative fundraising; neither is an additional fund or company raise. The platform retains existing Investor 3715 and remains distinct from unrelated Westlake businesses.

WuXi AppTec is the publicly listed pharmaceutical research, development and manufacturing corporate group led by WuXi AppTec Co., Ltd., a PRC joint-stock company listed on the Shanghai Stock Exchange (603259) and Hong Kong Stock Exchange (2359). Founded in2000, it provides an integrated CRDMO platform for discovery, development and commercial manufacturing of small-molecule drugs and emerging modalities including peptides and oligonucleotides, with operations across Asia, Europe and North America. Its own filings describe investment in AI-enabled drug discovery, lab automation, healthcare data and robotic chemistry. Ge Li is chairman and CEO, with co-CEOs Minzhang Chen and Steve Qing Yang. The current public directory publishes17 senior operational leaders; current HKEX filings separately identify11 board directors and company secretaries. WuXi AppTec also makes strategic corporate investments, including Engine Biosciences. It is a corporate operating platform and investor, not an independent VC fund; the legacy immutable InvestmentFirm type and Investor3651 are preserved to retain all historical references. WuXi Biologics (Cayman) Inc. is a separate listed issuer (2269.HK), and WuXi Healthcare Ventures is a separate existing investor record; neither is merged or substituted as the buyer. Corporate securities proceeds, cumulative investment balances and acquisitions are not external LP fund closes.

&AI is an artificial-intelligence software company founded in2024 by Caleb Harris and Herbert (Herbie) Turner. It builds a collaborative workspace for patent litigators, including prior-art research, claim charts, invalidity and infringement analysis. Its tools help professionals review cited evidence and prepare patent work products. Y Combinator identifies the company as a Summer2024 participant based in San Francisco. Its public leadership comprises CEO Caleb Harris and CTO Herbert Turner, accompanied by eight named external legal advisers. These advisers are not presented as employees or statutory directors. A complete engineering roster, exact legal incorporation details and appointment dates remain unpublished or unverified. The original &AI logo and genuine named company/investor portraits replace the previously generated nameplate. Existing organization ID AI is preserved. The issuer's February6,2025 announcement confirms a USD6.5M seed financing. Existing institutional and Liz Wessel personal investment records are retained. A legacy Signal-derived personal round reports USD7M on the same date; its cash amount and relationship to the issuer-announced round require reconciliation and are not treated here as another verified USD7M raise. Two legacy First Round organization references also require exact identity and protected-dependency review before consolidation. No additional cash, employee identities or investor tickets are inferred.

Alpaca provides API-first brokerage infrastructure for stocks, options, fixed income and crypto trading to financial institutions and developers.

ALT TEX operates in Manufacturing.

AOA Dx develops blood-based diagnostics for early detection of ovarian cancer using glycolipid biomarkers and its GlycoLocate platform.

Company operating in Climate & Energy.

Enterprise Software company.

Activeloop operates in AI.

Automated biology-laboratory company producing experimental protein data for AI-driven protein design, with an API for submitting and retrieving experiments.

Adaptyv Bio operates an automated protein-engineering foundry that lets researchers design, synthesize and experimentally test proteins.

Adravision builds AI dental-imaging software that detects cavities and other pathologies in radiographs for dentists and insurers.

Silicon-dominant battery materials for higher-energy lithium-ion cells.

Adventris Pharmaceuticals is a biotechnology company developing therapies and partnership programs in pharmaceutical research.

Adyn operates in Healthcare.

Affinity is a San Francisco software company building an AI-first CRM and relationship-intelligence platform for private-capital deal teams. Its software captures email, calendar and other interactions, models relationship strength, surfaces warm introductions, enriches company data and supports deal sourcing, fundraising and portfolio workflows. Its current Ascend agent platform acts on the CRM and relationship graph to prepare outreach, investment-committee materials and deal monitoring, with APIs and an MCP server. Founded in 2014 by Ray Zhou and Shubham Goel, the company is led by CEO Ken Fine, appointed in May 2024; both founders remain co-founders and board members. The current company site reports more than 3,300 private-capital firms using Affinity. Verified financings include a $13.5M Series A, $26.5M Series B in 2019 and $80M Series C in September 2021; the latter announcement reported $120M total funding. Affinity CRM is distinct from Ghana digital bank Affinity Africa and compliance-training company Affinity Learning at itsaffinity.com.

AfterQuery operates in Data & Analytics.

Agave operates in Food & Agriculture.

Identity-verification platform combining business and individual checks with fraud prevention and compliance workflows.

AI sales-outreach platform that identifies potential buyers using signals and generates personalized prospecting messages.

Airbyte operates in Data & Analytics.

Airmeet is a virtual and hybrid events platform for webinars, conferences, community events and audience engagement.

Climate & Energy company.

Company operating in AI.

Company operating in Fintech.

Albacore operates in Fintech.

Alex is an AI recruiting platform that interviews, screens and schedules job candidates over voice, video and text.

Biotech & Life Sciences company.

Alice.tech operates in SaaS.